Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.

Murray HW, Luster AD, Zheng H, Ma X.

Infect Immun. 2016 Dec 29;85(1). pii: e00824-16. doi: 10.1128/IAI.00824-16. Print 2017 Jan.

2.

IFN-γ-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver.

Murray HW, Mitchell-Flack M, Taylor GA, Ma X.

Exp Parasitol. 2015 Oct;157:103-9. doi: 10.1016/j.exppara.2015.07.005. Epub 2015 Jul 22.

3.

Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers.

Eiras DP, Kirkman LA, Murray HW.

Curr Treat Options Infect Dis. 2015 Mar 1;7(1):52-62.

4.

Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection.

Murray HW, Mitchell-Flack M, Zheng H, Ma X.

Infect Immun. 2015 Feb;83(2):702-12. doi: 10.1128/IAI.02418-14. Epub 2014 Dec 1.

5.

A randomized, controlled trial of the efficacy of an interoceptive exposure-based CBT for treatment-refractory outpatients with opioid dependence.

Otto MW, Hearon BA, McHugh RK, Calkins AW, Pratt E, Murray HW, Safren SA, Pollack MH.

J Psychoactive Drugs. 2014 Nov-Dec;46(5):402-11. doi: 10.1080/02791072.2014.960110.

6.

Cutaneous leishmaniasis in North Dakota.

Douvoyiannis M, Khromachou T, Byers N, Hargreaves J, Murray HW.

Clin Infect Dis. 2014 Sep 1;59(5):e73-5. doi: 10.1093/cid/ciu386. Epub 2014 May 20.

PMID:
24850800
7.

Anxiety sensitivity and interoceptive exposure: a transdiagnostic construct and change strategy.

Boswell JF, Farchione TJ, Sauer-Zavala S, Murray HW, Fortune MR, Barlow DH.

Behav Ther. 2013 Sep;44(3):417-31. doi: 10.1016/j.beth.2013.03.006. Epub 2013 Apr 2.

8.

Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.

Murray HW, Zhang Y, Zhang Y, Raman VS, Reed SG, Ma X.

Infect Immun. 2013 Jul;81(7):2318-26. doi: 10.1128/IAI.01468-12. Epub 2013 Apr 15.

9.

Predictors of dropout from psychosocial treatment in opioid-dependent outpatients.

McHugh RK, Murray HW, Hearon BA, Pratt EM, Pollack MH, Safren SA, Otto MW.

Am J Addict. 2013 Jan;22(1):18-22. doi: 10.1111/j.1521-0391.2013.00317.x.

10.

Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample.

McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW.

J Psychoactive Drugs. 2012 Jul-Aug;44(3):237-42.

11.

Psychometric Analysis of the Perceptions of Computerized Therapy Questionnaire-Patient Version (PCTQ-P).

Carper MM, McHugh RK, Murray HW, Barlow DH.

Adm Policy Ment Health. 2014 Jan;41(1):104-13. doi: 10.1007/s10488-012-0440-x.

PMID:
23011053
12.

Leishmaniasis in the United States: treatment in 2012.

Murray HW.

Am J Trop Med Hyg. 2012 Mar;86(3):434-40. doi: 10.4269/ajtmh.2012.11-0682. Review.

13.

Shared Variance among Self-Report and Behavioral Measures of Distress Intolerance.

McHugh RK, Daughters SB, Lejuez CW, Murray HW, Hearon BA, Gorka SM, Otto MW.

Cognit Ther Res. 2011 Jun;35(3):266-275.

14.

Anxiety sensitivity and illicit sedative use among opiate-dependent women and men.

Hearon BA, Calkins AW, Halperin DM, McHugh RK, Murray HW, Otto MW.

Am J Drug Alcohol Abuse. 2011 Jan;37(1):43-7. doi: 10.3109/00952990.2010.535581. Epub 2010 Nov 19. Erratum in: Am J Drug Alcohol Abuse. 2011 Jan;37(1):47.

15.

Attentional bias and craving in smokers: the impact of a single attentional training session.

McHugh RK, Murray HW, Hearon BA, Calkins AW, Otto MW.

Nicotine Tob Res. 2010 Dec;12(12):1261-4. doi: 10.1093/ntr/ntq171. Epub 2010 Oct 20.

PMID:
20961974
16.

Non-oral treatment with ivermectin for disseminated strongyloidiasis.

Fusco DN, Downs JA, Satlin MJ, Pahuja M, Ramos L, Barie PS, Fleckenstein L, Murray HW.

Am J Trop Med Hyg. 2010 Oct;83(4):879-83. doi: 10.4269/ajtmh.2010.10-0258.

17.

Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.

Murray HW.

Future Microbiol. 2010 Sep;5(9):1301-3. doi: 10.2217/fmb.10.92. No abstract available.

18.

Development and validation of the smoking cue appeal survey.

Murray HW, McHugh RK, Rowley TC, Sirota AD, Otto MW.

Subst Use Misuse. 2010 Nov;45(13):2152-61. doi: 10.3109/10826084.2010.481771. Epub 2010 May 14.

PMID:
20469971
19.

Single-dose liposomal amphotericin B for visceral leishmaniasis in India.

Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.

N Engl J Med. 2010 Feb 11;362(6):504-12. doi: 10.1056/NEJMoa0903627.

20.

Balancing fidelity and adaptation in the dissemination of empirically-supported treatments: The promise of transdiagnostic interventions.

McHugh RK, Murray HW, Barlow DH.

Behav Res Ther. 2009 Nov;47(11):946-53. doi: 10.1016/j.brat.2009.07.005. Epub 2009 Jul 29. Review.

21.

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.

Clin Infect Dis. 2008 Oct 15;47(8):1000-6. doi: 10.1086/591972.

PMID:
18781879
22.

Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.

Murray HW.

Infect Immun. 2008 Sep;76(9):4088-91. doi: 10.1128/IAI.00490-08. Epub 2008 Jun 23.

23.

Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.

Mannelli P, Patkar AA, Peindl K, Murray HW, Wu LT, Hubbard R.

J Clin Psychopharmacol. 2007 Oct;27(5):468-74.

PMID:
17873678
24.

Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.

Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW.

Clin Infect Dis. 2007 Sep 1;45(5):556-61. Epub 2007 Jul 23.

PMID:
17682988
25.
26.
27.

Changes in tobacco smoking following treatment for cocaine dependence.

Patkar AA, Mannelli P, Peindl K, Murray HW, Meier B, Leone FT.

Am J Drug Alcohol Abuse. 2006;32(2):135-48.

PMID:
16595320
28.

Visceral Leishmania donovani infection in interleukin-13-/- mice.

Murray HW, Tsai CW, Liu J, Ma X.

Infect Immun. 2006 Apr;74(4):2487-90.

29.

Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody.

Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW.

J Clin Microbiol. 2006 Jan;44(1):251-3.

30.

Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.

Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB.

Parasitology. 2005 Dec;131(Pt 6):747-57.

PMID:
16336728
31.

Advances in leishmaniasis.

Murray HW, Berman JD, Davies CR, Saravia NG.

Lancet. 2005 Oct 29-Nov 4;366(9496):1561-77. Review.

PMID:
16257344
32.

Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals.

Mannelli P, Patkar AA, Murray HW, Certa K, Peindl K, Mattila-Evenden M, Berrettini WH.

Addict Biol. 2005 Sep;10(3):261-8.

PMID:
16109588
33.

Availability of miltefosine for the treatment of kala-azar in India.

Sundar S, Murray HW.

Bull World Health Organ. 2005 May;83(5):394-5. Epub 2005 Jun 24. No abstract available.

34.

Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J, Ma X.

Infect Immun. 2005 Jul;73(7):3903-11.

36.
37.

Treatment of visceral leishmaniasis in 2004.

Murray HW.

Am J Trop Med Hyg. 2004 Dec;71(6):787-94. Review. Erratum in: Am J Trop Med Hyg. 2005 Mar;72(3):359.

PMID:
15642973
38.

Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.

Murray HW.

Expert Rev Anti Infect Ther. 2004 Apr;2(2):279-92. Review. Erratum in: Expert Rev Anti Infect Ther. 2004 Jun;2(3):462.

PMID:
15482193
39.

A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan.

Amprey JL, Im JS, Turco SJ, Murray HW, Illarionov PA, Besra GS, Porcelli SA, Späth GF.

J Exp Med. 2004 Oct 4;200(7):895-904.

40.

Pre-treatment measures of impulsivity, aggression and sensation seeking are associated with treatment outcome for African-American cocaine-dependent patients.

Patkar AA, Murray HW, Mannelli P, Gottheil E, Weinstein SP, Vergare MJ.

J Addict Dis. 2004;23(2):109-22.

PMID:
15132346
41.

Malaria: 30 years of experience at a New York City teaching hospital.

Kambili C, Murray HW, Golightly LM.

Am J Trop Med Hyg. 2004 Apr;70(4):408-11.

PMID:
15100455
42.

Drugs against leishmaniasis: a synergy of technology and partnerships.

Davis AJ, Murray HW, Handman E.

Trends Parasitol. 2004 Feb;20(2):73-6. Review.

PMID:
14747020
43.

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.

Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.

Clin Infect Dis. 2004 Feb 1;38(3):377-83. Epub 2004 Jan 13.

PMID:
14727208
44.

Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.

Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP.

Infect Immun. 2003 Nov;71(11):6453-62.

45.

High- and low-structure treatments for substance dependence: role of learned helplessness.

Thornton CC, Patkar AA, Murray HW, Mannelli P, Gottheil E, Vergare MJ, Weinstein SP.

Am J Drug Alcohol Abuse. 2003 Aug;29(3):567-84.

PMID:
14510041
46.

Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Murray HW, Brooks EB, DeVecchio JL, Heinzel FP.

Antimicrob Agents Chemother. 2003 Aug;47(8):2513-7.

47.

Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.

Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, Heinzel FP.

J Infect Dis. 2003 Aug 1;188(3):458-64. Epub 2003 Jul 14.

PMID:
12870129
48.

Nicotine dependence and treatment outcome among African American cocaine-dependent patients.

Patkar AA, Vergare MJ, Thornton CC, Weinstein SP, Murray HW, Leone FT.

Nicotine Tob Res. 2003 Jun;5(3):411-8.

PMID:
12791537
49.

Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal.

Patkar AA, Gopalakrishnan R, Naik PC, Murray HW, Vergare MJ, Marsden CA.

Alcohol Alcohol. 2003 May-Jun;38(3):224-31.

PMID:
12711656
50.

A novel defect in interferon-gamma secretion in patients with refractory nontuberculous pulmonary mycobacteriosis.

Safdar A, Armstrong D, Murray HW.

Ann Intern Med. 2003 Mar 18;138(6):521. No abstract available.

PMID:
12639099

Supplemental Content

Loading ...
Support Center